Discounts and rebates lead to lower net prices for insulin. So why are PBMs and insurers making patients pay based off list price httpsonphr.ma2YZduj8Âpic.twitter.comRyaPZ5cdbf

Discounts and rebates lead to lower net prices for insulin. So why are PBMs and insurers making patients pay based off list price? https://onphr.ma/2YZduj8 pic.twitter.com/RyaPZ5cdbf

19:30 EDT 9 Apr 2019 | PhRMA

Discounts and rebates lead to lower net prices for insulin. So why are PBMs and insurers making patients pay based off list price? https://onphr.ma/2YZduj8  pic.twitter.com/RyaPZ5cdbf

More From BioPortfolio on "Discounts and rebates lead to lower net prices for insulin. So why are PBMs and insurers making patients pay based off list price? https://onphr.ma/2YZduj8 pic.twitter.com/RyaPZ5cdbf"